1-20 of 28
Tamar Uziel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 4713: Elucidating the mechanism of clinical Teliso-v (cMet-MMAE ADC) and osimertinib combination: A CAV1 and EGFR multi-protein complex controls endolysosomal trafficking of Teliso-V

Free
Izhar Batth, Ronald Pandoy, Lisa Roberts-Rapp, Athan Vasilopoulos, Peter Ansell, Vincent Blot, Gregory K. Potts, Janice Y. Lee, Hua Tang, Jon D. Williams, Tamar Uziel, PK Epling-Burnette
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 4713.
https://doi.org/10.1158/1538-7445.AM2025-4713
Published: 21 April 2025
View articletitled, Abstract 4713: Elucidating the mechanism of clinical Teliso-v (cMet-MMAE ADC) and osimertinib combination: A CAV1 and EGFR multi-protein complex controls endolysosomal trafficking of Teliso-V
Journal Articles

Abstract ND01: ABBV-303: A novel NK and CD8 T cell engager specific for c-Met-expressing tumors

Free
Jennifer Stone, Kamonwan Pear Fish, Devika Ashok, Laura McKay, Saeed Akhand, Weilong Zhao, Si Wu, Amani Makkouk, Cormac Cosgrove, Paul Ellis, David Peetz, Stephanie Shee, Richard Peterson, II, Shelby Anderson, Adam Chervin, Claudina Stevenson, Tamar Uziel, Edward Reilly
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): ND01.
https://doi.org/10.1158/1538-7445.AM2024-ND01
Published: 05 April 2024
View articletitled, Abstract ND01: ABBV-303: A novel NK and CD8 T cell engager specific for c-Met-expressing tumors
Journal Articles

Abstract 2116: Telisotuzumab vedotin (Teliso-V)-mediated c-Met internalization, endolysosomal trafficking, and potent cytotoxic activity are unaffected by MET exon-14 skipping mutation

Free
Izhar Batth, Ronald Pandoy, Shamim Khaja, Dolonchampa Maji, Tamar Uziel, Athan Vasilopoulos, Peter Ansell, PK Epling-Burnette
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 2116.
https://doi.org/10.1158/1538-7445.AM2024-2116
Published: 22 March 2024
View articletitled, Abstract 2116: Telisotuzumab vedotin (Teliso-V)-mediated c-Met internalization, endolysosomal trafficking, and potent cytotoxic activity are unaffected by MET exon-14 skipping mutation
Journal Articles

Abstract CT257: First-in-human phase 1 studies of PTPN2/1 inhibitors ABBV-CLS-484 and ABBV-CLS-579 in locally advanced or metastatic tumors

Free
Patricia M. LoRusso, Emiliano Calvo Aller, Noboru Yamamoto, Chia-Chi Lin, Thaddeus Beck, David Sommerhalder, Do-Youn Oh, John D. Powderly, Talia Golan, Linu Sara Abraham, Joel S. Hayflick, Tamar Uziel, Priya Brunsdon, Wijith Munasinghe, Marcia Paddock, Cathleen Brdlik Hartman, Jonathan Powell, Bruno Medeiros, Martha R. Neagu, Benedito A. Carneiro
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT257.
https://doi.org/10.1158/1538-7445.AM2023-CT257
Published: 14 April 2023
View articletitled, Abstract CT257: First-in-human phase 1 studies of PTPN2/1 inhibitors ABBV-CLS-484 and ABBV-CLS-579 in locally advanced or metastatic tumors
Journal Articles

Abstract 540: c-MET mutations sensitize to antibody-drug conjugate telisotuzumab vedotin through efficient internalization and rapid intracellular drug delivery

Free
Izhar S. Batth, Bijay S. Jaiswal, Dolonchampa Maji, Robert Sparks, William Glauser, Tamar Uziel, D. Ross Camidge, Athan Vasilopoulos, Peter Ansell, PK Epling-Burnette
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 540.
https://doi.org/10.1158/1538-7445.AM2023-540
Published: 04 April 2023
View articletitled, Abstract 540: c-MET mutations sensitize to antibody-drug conjugate telisotuzumab vedotin through efficient internalization and rapid intracellular drug delivery
Journal Articles

Abstract 2530: DELE1 loss and dysfunctional integrated stress signaling in TP53 mutated AML is a novel pathway for venetoclax resistance

Free
David Sharon, Paul Jung, Yan Sun, Weiguo Feng, Ziping Yang, Valerie Robinson, Diya Mitra, Wei Liu, Pingping Zheng, Tamar Uziel, Lloyd Lam, Mark D. Minden, Jeremy Ross, Wellington Mendes, Jalaja Potluri, Andrew H. Wei, Marina Konopleva, Monique Dail, Brenda Chyla, PK Epling-Burnette
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2530.
https://doi.org/10.1158/1538-7445.AM2023-2530
Published: 04 April 2023
View articletitled, Abstract 2530: DELE1 loss and dysfunctional integrated stress signaling in TP53 mutated AML is a novel pathway for venetoclax resistance
Journal Articles

Abstract 6308: Preclinical development of ABBV-319: a CD19-targeting glucocorticoid receptor modulator (GRM) agonist antibody-drug conjugate (ADC) for the treatment of B-cell malignancies

Free
Chewei Anderson Chang, Ethan Emberley, Aloma L. D'Souza, Weilong Zhao, Cormac Cosgrove, Axel Hernandez Jr, Anatol Oleksijew, Paul Ellis, Luis Rodriguez, Gail Bukofzer, David Peetz, Wissam Assaily, Raghuveer Singh Mali, Wei Liu, Danqing Xu, Gregory K. Potts, Shaun McLoughlin, Kimberley McCarthy, Zhaomei Zhang, Jos Campbell, Isabella Sturdevant, Gloria Zhang, Tyler Curran, Jon D. Williams, Erwin Boghaert, Milan Bruncko, Christopher C. Marvin, Adrian Hobson, Michael Mcpherson, Tamar Uziel, Marybeth Pysz, Xi Zhao, Alex Bankovich, Kevin J. Freise, Susan Morgan-Lappe, James W. Purcell
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6308.
https://doi.org/10.1158/1538-7445.AM2023-6308
Published: 04 April 2023
View articletitled, Abstract 6308: Preclinical development of ABBV-319: a CD19-targeting glucocorticoid receptor modulator (GRM) agonist antibody-drug conjugate (ADC) for the treatment of B-cell malignancies
Journal Articles

Abstract 3831: Selective targeting BET family BDII bromodomain with ABBV-744 and BCL-2 with venetoclax (ABT-199) is synergistic in primary acute myeloid leukemia models

Free
Tianyu Cai, Vinitha Kuruvilla, Xiaoyu Lin, Tamar Uziel, Xin Lu, Lu Zhang, Qi Zhang, Lina Han, Antonio Cavazos, Yu Shen, Marina Konopleva
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3831.
https://doi.org/10.1158/1538-7445.AM2019-3831
Published: 01 July 2019
View articletitled, Abstract 3831: Selective targeting BET family BDII bromodomain with ABBV-744 and BCL-2 with venetoclax (ABT-199) is synergistic in primary acute myeloid leukemia models
Journal Articles

LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates

Free
James W. Purcell, Sonia G. Tanlimco, Jonathan Hickson, Melvin Fox, Mien Sho, Lisa Durkin, Tamar Uziel, Rick Powers, Kelly Foster, Thomas McGonigal, Subashri Kumar, Josue Samayoa, Dong Zhang, Joann P. Palma, Sasmita Mishra, Diane Hollenbaugh, Kurt Gish, Susan E. Morgan-Lappe, Eric D. Hsi, Debra T. Chao
Journal: Cancer Research
Cancer Res (2018) 78 (14): 4059–4072.
https://doi.org/10.1158/0008-5472.CAN-18-0327
Published: 15 July 2018
View articletitled, LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
Open the PDF for LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates in another window
Includes: Supplementary data
Journal Articles

Abstract 800: ABBV-744, a first-in-class and highly selective inhibitor of the second bromodomain of BET family proteins, displays robust activities in preclinical models of acute myelogenous leukemia

Free
Xiaoyu Lin, Xiaoli Huang, Richard Bellin, Emily Faivre, Paul Hessler, Lloyd Lam, Mai Ha Bui, Denise Wilcox, Tamar Uziel, Debra C. Ferguson, Terrance J. Magoc, Daniel H. Albert, Keith F. McDaniel, Warren Kati, Yu Shen
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 800.
https://doi.org/10.1158/1538-7445.AM2018-800
Published: 01 July 2018
View articletitled, Abstract 800: ABBV-744, a first-in-class and highly selective inhibitor of the second bromodomain of BET family proteins, displays robust activities in preclinical models of acute myelogenous leukemia
Journal Articles

Abstract LB-261: Targeting BET Family Bromodomain with ABBV-075 and BCL-2 with venetoclax (ABT-199) is synergistic in primary acute myeloid leukemia models

Free
Tianyu Cai, Vinitha Mary Kuruvilla, Tamar Uziel, Qi Zhang, Lina Han, Antonio Cavazos, Yu Shen, Marina Konopleva
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): LB-261.
https://doi.org/10.1158/1538-7445.AM2018-LB-261
Published: 01 July 2018
View articletitled, Abstract LB-261: Targeting BET Family Bromodomain with ABBV-075 and BCL-2 with venetoclax (ABT-199) is synergistic in primary acute myeloid leukemia models
Journal Articles

Abstract 4960: First-in-class, highly BDII-selective BET family inhibitor ABBV-744 displays potent anti-tumor activity in androgen receptor positive prostate cancer models and an improved tolerability profile

Free
Emily J. Faivre, Denise Wilcox, Mai Ha-Bui, Paul Hessler, Vasudha Sehgal, Xin Lu, Tamar Uziel, Gaurav Mehta, Daniel H. Albert, Keith McDaniel, Warren Kati, Yu Shen
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4960.
https://doi.org/10.1158/1538-7445.AM2018-4960
Published: 01 July 2018
View articletitled, Abstract 4960: First-in-class, highly BDII-selective BET family inhibitor ABBV-744 displays potent anti-tumor activity in androgen receptor positive prostate cancer models and an improved tolerability profile
Journal Articles

Abstract 3812: JAK2 and PTPN11 mutations as potential biomarkers for BCL-xL inhibition as monotherapy and in combination therapy for acute myeloid leukemia

Free
Richard J. Bellin, Valerie Hilgenberg, Relja Popovic, Tamar Uziel, Lloyd T. Lam
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3812.
https://doi.org/10.1158/1538-7445.AM2017-3812
Published: 01 July 2017
View articletitled, Abstract 3812: JAK2 and PTPN11 mutations as potential biomarkers for BCL-xL inhibition as monotherapy and in combination therapy for acute myeloid leukemia
Journal Articles

Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies

Free
Mai H. Bui, Xiaoyu Lin, Daniel H. Albert, Leiming Li, Lloyd T. Lam, Emily J. Faivre, Scott E. Warder, Xiaoli Huang, Denise Wilcox, Cherrie K. Donawho, George S. Sheppard, Le Wang, Steve Fidanze, John K. Pratt, Dachun Liu, Lisa Hasvold, Tamar Uziel, Xin Lu, Fred Kohlhapp, Guowei Fang, Steven W. Elmore, Saul H. Rosenberg, Keith F. McDaniel, Warren M. Kati, Yu Shen
Journal: Cancer Research
Cancer Res (2017) 77 (11): 2976–2989.
https://doi.org/10.1158/0008-5472.CAN-16-1793
Published: 31 May 2017
View articletitled, Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies
Open the PDF for Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies in another window
Includes: Supplementary data
Journal Articles

Abstract 3770: HEXIM1 as a pharmacodynamic marker for monitoring target engagement of ABBV-075

Free
Xiaoli Huang, Xiaoyu Lin, Leiming Li, Rongqi Wang, Lisa Roberts, Paul Hessler, Tamar Uziel, Lloyd Lam, Terry Magoc, Daniel H. Albert, Steven W. Elmore, Guowei Fang, Saul H. Rosenberg, Keith McDaniel, Warren Kati, Yu Shen
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3770.
https://doi.org/10.1158/1538-7445.AM2016-3770
Published: 15 July 2016
View articletitled, Abstract 3770: HEXIM1 as a pharmacodynamic marker for monitoring target engagement of ABBV-075
Journal Articles

Abstract 420: Translational strategy for targeting MCL1 amplified tumors with CDK9 inhibitor

Free
Ziping Yang, Ricky Bellin, Paul Hessler, Xin Lu, Tamar Uziel, Lloyd T. Lam
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 420.
https://doi.org/10.1158/1538-7445.AM2016-420
Published: 15 July 2016
View articletitled, Abstract 420: Translational strategy for targeting MCL1 amplified tumors with CDK9 inhibitor
Journal Articles

Abstract 4694: ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo

Free
Emily J. Faivre, Denise M. Wilcox, Paul Hessler, Tamar Uziel, Paul Tapang, Terry Magoc, Daniel H. Albert, Guowei Fang, Saul Rosenberg, Keith McDaniel, Keith McDaniel, Warren Kati, Yu Shen
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4694.
https://doi.org/10.1158/1538-7445.AM2016-4694
Published: 15 July 2016
View articletitled, Abstract 4694: ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo
Journal Articles

Abstract 4738: The BET family bromodomain inhibitor ABBV-075 is a promising therapeutic agent for acute myeloid leukemia and myelodysplastic syndrome

Free
Mai H. Bui, Xiaoyu Lin, Xiaoli Huang, Leiming Li, Aparna Sarthy, Daniel Albert, Terry Magoc, Lloyd Lam, Paul Hessler, Tamar Uziel, Steven Elmore, Keith McDaniel, Warren Kati, Yu Shen
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4738.
https://doi.org/10.1158/1538-7445.AM2016-4738
Published: 15 July 2016
View articletitled, Abstract 4738: The BET family bromodomain inhibitor ABBV-075 is a promising therapeutic agent for acute myeloid leukemia and myelodysplastic syndrome
Journal Articles

Abstract 4692: Targeting the BET bromodomain proteins and anti-apoptotic protein BCL2 in small cell lung cancer

Free
Lloyd T. Lam, Xiaoyu Lin, Emily Faivre, Ziping Yang, Xiaoli Huang, Ricky Bellin, Xin Lu, Yu Shen, Tamar Uziel
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4692.
https://doi.org/10.1158/1538-7445.AM2016-4692
Published: 15 July 2016
View articletitled, Abstract 4692: Targeting the BET bromodomain proteins and anti-apoptotic protein BCL2 in small cell lung cancer
Journal Articles

Abstract 3085: The BET family bromodomain inhibitor ABBV-075 targets multiple pathogenesis factors in multiple myeloma and exhibits robust in vivo efficacies as a single agent and in combination with bortezomib

Free
Tamar Uziel, Xiaoyu Lin, Emily Faivre, Aparna Sarthy, Daniel H. Albert, Leiming Li, Denise Wilcox, Xiaoli Huang, Terry Magoc, Lloyd Lam, Steven W. Elmore, Keith McDaniel, Warren Kati, Yu Shen
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3085.
https://doi.org/10.1158/1538-7445.AM2016-3085
Published: 15 July 2016
View articletitled, Abstract 3085: The BET family bromodomain inhibitor ABBV-075 targets multiple pathogenesis factors in multiple myeloma and exhibits robust in vivo efficacies as a single agent and in combination with bortezomib